OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SMOL57

Smruthi Organics Ltd

PharmaceuticalsVerified

Smruthi Organics Ltd has a liquidity profile that is medium, with a current ratio of 2.04, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has negative net cash after subtracting total debt, which suggests potential liquidity constraints. The company's debt-to-equity ratio is 0.24, which is relatively low, indicating a conservative capital structure. In terms of profitability, Smruthi Organics Ltd has a return on equity (ROE) of 4.97% and a return on assets (ROA) of 3.19%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming its peers in terms of generating returns for shareholders and asset utilization. The company's revenue is derived from two main segments: Bulk Drugs and Drugs Intermediates, and Formulation. Geographically, Smruthi Organics Ltd serves both the Indian domestic market and the rest of the world, with clients in Asia, the Americas, and Africa. However, the input data does not provide specific revenue concentration figures for these segments or regions. Looking at the growth trajectory, the input data does not provide specific numeric deltas for the current or next fiscal year. However, the company's operating cash flow of INR 99.76 million and free cash flow of INR -41.68 million suggest that the company is investing in capital expenditures, with a capital expenditure of INR -115.15 million. This investment could be a sign of future growth, but the negative free cash flow indicates that the company is spending more on capital than it is generating in cash from operations. The risk assessment for Smruthi Organics Ltd indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is the negative net cash after subtracting total debt, which could pose a risk to its liquidity. The dilution risk is low, suggesting that the company is not expected to issue additional shares in the near term that would significantly dilute existing shareholders. Recent events and filings for Smruthi Organics Ltd are not detailed in the input data. However, the company's financial snapshot and risk assessment provide insights into its current financial health and potential risks. The company's capital expenditures and operating cash flow suggest that it is investing in its operations, which could be a positive sign for future growth.

30-day price · SMOL+13.01 (+12.8%)
Low$95.00High$123.37Close$115.00As of15 May, 00:00 UTC
Profile
CompanySmruthi Organics Ltd
TickerSMOL.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Smruthi Organics Ltd is an India-based active pharmaceutical ingredients (API) manufacturer that produces and sells API products in the anti-diabetic, anti-hypertension, and anti-infectives therapeutic categories to pharmaceutical companies in India and globally.

Classification. Smruthi Organics Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Smruthi Organics Ltd has a liquidity profile that is medium, with a current ratio of 2.04, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has negative net cash after subtracting total debt, which suggests potential liquidity constraints. The company's debt-to-equity ratio is 0.24, which is relatively low, indicating a conservative capital structure. In terms of profitability, Smruthi Organics Ltd has a return on equity (ROE) of 4.97% and a return on assets (ROA) of 3.19%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming its peers in terms of generating returns for shareholders and asset utilization. The company's revenue is derived from two main segments: Bulk Drugs and Drugs Intermediates, and Formulation. Geographically, Smruthi Organics Ltd serves both the Indian domestic market and the rest of the world, with clients in Asia, the Americas, and Africa. However, the input data does not provide specific revenue concentration figures for these segments or regions. Looking at the growth trajectory, the input data does not provide specific numeric deltas for the current or next fiscal year. However, the company's operating cash flow of INR 99.76 million and free cash flow of INR -41.68 million suggest that the company is investing in capital expenditures, with a capital expenditure of INR -115.15 million. This investment could be a sign of future growth, but the negative free cash flow indicates that the company is spending more on capital than it is generating in cash from operations. The risk assessment for Smruthi Organics Ltd indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is the negative net cash after subtracting total debt, which could pose a risk to its liquidity. The dilution risk is low, suggesting that the company is not expected to issue additional shares in the near term that would significantly dilute existing shareholders. Recent events and filings for Smruthi Organics Ltd are not detailed in the input data. However, the company's financial snapshot and risk assessment provide insights into its current financial health and potential risks. The company's capital expenditures and operating cash flow suggest that it is investing in its operations, which could be a positive sign for future growth.
Key takeaways
  • Smruthi Organics Ltd has a conservative capital structure with a low debt-to-equity ratio of 0.24.
  • The company's return on equity and return on assets are below the industry median, indicating underperformance in generating returns.
  • The company's liquidity is medium, with a current ratio of 2.04, but it has negative net cash after subtracting total debt.
  • Smruthi Organics Ltd is investing in capital expenditures, with a capital expenditure of INR -115.15 million, which could be a sign of future growth.
  • The company has a low dilution risk, suggesting that it is not expected to issue additional shares in the near term that would significantly dilute existing shareholders.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.26B
Gross profit$434.8M
Operating income$66.6M
Net income$35.6M
R&D
SG&A
D&A
SBC
Operating cash flow$99.8M
CapEx-$115.2M
Free cash flow-$41.7M
Total assets$1.12B
Total liabilities$401.1M
Total equity$716.3M
Cash & equivalents$4.4M
Long-term debt$168.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$716.3M
Net cash-$164.4M
Current ratio2.0
Debt/Equity0.2
ROA3.2%
ROE5.0%
Cash conversion2.8%
CapEx/Revenue-9.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricSMOLActivity
Op margin5.3%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin2.8%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin34.5%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-9.1%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity24.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 20:05 UTC#52f8e343
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 20:06 UTCJob: 83ff0b64